Sex (male vs female) | 1.02 (0.64–1.64) | 0.9259 | | |
Age at study start | 1.02 (1.01–1.03) | < 0.0001 | 1.02 (1.01–1.03) | < 0.0001 |
White vs non-white | 1.15 (0.85–1.56) | 0.3671 | | |
Disease duration at study entry | 1.01 (1–1.03) | 0.1382 | | |
Study starting date after year 2000 vs before | 0.74 (0.56–0.97) | 0.0274 | 0.65 (0.49–0.87) | 0.0004 |
SDI score at study entry | 1.15 (1.05–1.25) | 0.0014 | 1.05 (0.96–1.14) | 0.3205 |
Antimalarials (yes vs no) at study entry | 0.92 (0.7–1.21) | 0.5551 | | |
Immunosuppressants (yes vs no) at study entry | 1.31 (0.99–1.74) | 0.0613 | 1.64 (1.20–2.23) | 0.0017 |
Entry SLEDAI-2K ≥ 8 vs entry SLEDAI-2K 6 or 7 | 1.56 (1.04–2.34) | 0.0304 | 1.70 (1.13–2.55) | 0.0104 |